WO2023067569 - STABLE READY TO DILUTE COMPOSITION OF CARFILZOMIB
National phase entry is expected:
Publication Number
WO/2023/067569
Publication Date
27.04.2023
International Application No.
PCT/IB2022/060145
International Filing Date
21.10.2022
Title **
[English]
STABLE READY TO DILUTE COMPOSITION OF CARFILZOMIB
[French]
COMPOSITION STABLE PRÊTE À DILUER DE CARFILZOMIB
Applicants **
KASHIV BIOSCIENCES, LLC
20, New England Avenue
Piscataway, New Jersey 08854, US
Inventors
VASANANI, Paras Rasiklal
D-404, Silver pearl apartment
Opp. Aryan flats, Chankyapuri road
Behind Ganesh Meridian, Ghatlodia, Gujarat
Ahmedabad 380061, IN
MEHTA, Sandip Pareshbhai
D/74, New Jash park society, Ishanpur, Ahmedabad
Gujarat
Ahmedabad 382443, IN
Priority Data
202121047991
21.10.2021
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1343 | |
| EPO | Filing, Examination | 8652 | |
| Japan | Filing | 593 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 4805 |
Total: 15968 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The invention is directed to room temperature stable injectable formulations of carfilzomib or its pharmaceutically acceptable derivatives thereof in the form of ready to dilute solution and concentrates with no hemolytic potential. Further the invention is directed to a method for treating patients with relapsed or refractory multiple myeloma by administering such composition.[French]
L'invention concerne des formulations injectables stables à température ambiante de carfilzomib ou de ses dérivés pharmaceutiquement acceptables sous la forme d'une solution prête à diluer et de concentrés sans potentiel hémolytique. L'invention concerne en outre un procédé de traitement de patients atteints d'un myélome multiple récidivant ou réfractaire par administration d'une telle composition.